SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Sponsor
Huihua Xiong
Study ID
NCT06361979
Phase
PHASE2
Status
Unknown

Conditions

  • Breasr Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-A1811 — DRUG
    SHR-A1811: intravenous
  • Bevacizumab — DRUG
    Bevacizumab:intravenous

Study Details

This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases

Key Dates

First listed
Apr 12, 2024
Start date
May 31, 2024
Status verified
Apr 2024
Primary completion
May 31, 2025
Completion
May 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ARM1

Primary Outcome Measure

CNS-ORR [ Time Frame: Up to 2 years ]

Central Contacts